Needham Lifts PT on Neumora Therapeutics (NMRA) to $8 From $6, Keeps a Buy Rating

Group 1 - Neumora Therapeutics, Inc. (NASDAQ:NMRA) is recognized as one of the best stocks under $5 with significant upside potential, with Needham raising its price target from $6 to $8 while maintaining a Buy rating [1] - Guggenheim upgraded Neumora Therapeutics, Inc. from Neutral to Buy on October 27, setting a price target of $14, citing compelling preclinical obesity data as a key factor [2] - The company focuses on integrating neuroscience and data science to develop precision medicine for brain diseases, particularly targeting therapeutically relevant areas in CNS diseases [2] Group 2 - The positive outlook for Neumora Therapeutics is driven by its broad pipeline showcased during the R&D Investor Event, which has increased investor optimism [1] - Guggenheim highlighted the NLRP3i program in obesity and related disorders as a significant driver for value creation for Neumora Therapeutics [2]